Catalog No. | HB996096 |
---|---|
Species reactivity | Human |
Applications | Research Grade Biosimilar |
Isotype | (scFv-kappa-heavy)-G1_L-kappa-(scFv-heavy-kappa)-(scFv-heavy-kappa) |
Expression system | Mammalian Cells |
Clonality | Monoclonal |
Target | CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain, Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Protein A/G, purified from cell culture supernatant. |
Accession | P15391 & Q9NZQ7 & P07766 & Q07011 |
Form | Liquid |
Storage buffer | 0.01M PBS,pH7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names | GNC038,GNC-038,GNC038,CAS:2559704-23-1 |
Background | Emfizatamab is an anti-CD19/CD3E/TNFRSF9/PD-L1 monoclonal antibody. |
Note | For research use only. Not for use in clinical or therapeutic applications. |
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France